⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Citi boosts Healthpeak Properties stock PT, maintains Neutral rating amid 2024 FFOps stability

EditorAhmed Abdulazez Abdulkadir
Published 21/08/2024, 23:08
DOC
-

On Wednesday, Citi updated its price target for Healthpeak Properties Inc (NYSE:DOC), increasing it to $22 from the previous $20, while the firm retained a Neutral stance on the stock. This adjustment follows the company's second-quarter earnings report and takes into account revised operational, financing, and transactional assumptions.

The firm's analysis led to the maintenance of its 2024 core Funds From Operations (FFOps) per share estimate at $1.79. However, the estimate for 2025's core FFOps per share has been slightly reduced to $1.84, down from $1.85. The revision in the price target reflects these updated projections.

In a statement released, Citi highlighted the reasons behind the new price target, stating, "Following 2Q earnings, we are updating our DOC model for updated operating, financing, and transaction assumptions." The firm's decision to adjust its price target is directly linked to the recent quarterly financial outcomes and future expectations for Healthpeak Properties.

Healthpeak Properties, a real estate investment trust, focuses on properties serving the healthcare industry, including sectors such as senior housing, life science, and medical offices. The updated estimates and price target from Citi suggest a cautious but slightly more optimistic outlook for the company's financial performance.

Investors and market watchers will note the new $22 price target as a point of reference for Healthpeak Properties' stock performance in the market. The maintained Neutral rating indicates that while expectations have improved, Citi remains reserved in its overall assessment of the stock’s growth potential.

In other recent news, Healthpeak Properties has witnessed significant developments, including robust earnings results, strategic mergers, and analyst upgrades. The company's earnings report was strong, leading to RBC Capital and Evercore ISI increasing their price targets for Healthpeak Properties to $25 and $24 respectively. Baird also raised its price target to $24, citing the company's operational management strength, lab improvements, and merger synergies.

Healthpeak's merger with Physicians Realty (NYSE:DOC_OLD) brought additional scale and tenant relationships, further strengthening its position. The company also fully acquired King Street Properties' minority stake in their joint venture, expanding Healthpeak's greater Boston portfolio to a total of 2.7 million square feet.

In addition, Healthpeak has raised its 2024 earnings guidance following a strong first quarter, fueled by robust same-store performance, the successful integration of Physicians Realty, and strategic stock buybacks. The company plans to internalize an additional four million square feet by year-end, targeting more than 70% of its total footprint for internalization in 2025 and '26.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.